Hemoglobinopathy Market is expected to reach US$ 277.9 Mn by 2028 at a CAGR of 7.4% during the forecast period

Hemoglobinopathies are one of the most typical hereditary diseases in the globe. The conditions may be segmented into two group’s namely structural hemoglobin variants and thalassemia syndromes. Alpha thalassemia and Beta thalassemia are some major types and the typical variants of structural hemoglobin are HbE,HbC and HbS.

The global hemoglobinopathy treatment market is projected to be valued at US$ 523.4 Million in 2019 and is expected to reach US$ 1,001.6 Million by the end of 2027.

Global Hemoglobinopathy Treatment Market: Drivers

Rising pervasiveness of thalassemia is expected to fuel the global hemoglobinopathy treatment market growth over the forecast period. For instance, the March 2019 study, published in the BioMed Research International journal, ‘Alpha-Thalassemia in North Morocco: Prevalence and Molecular Spectrum’, the α-thalassemia ubiquity in newborns was found to be 26.59%.

Request For Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/2801

Global Hemoglobinopathy Treatment Market: Opportunities

Research and Development in the sphere of hemoglobinopathies is expected to provide rewarding growth opportunities to industries in the global hemoglobinopathy treatment market. For instance, researchers at The University of British Columbia and Canada, in February 2019, reported evaluation of serum non-transferring bound iron, a poisonous biochemical that is accumulated in the blood when there is absorption of high amounts of iron, in Cambodian women who were provided with iron supplements every day according to the 2016 guidelines by global World Health Organization (WHO).

Global Hemoglobinopathy Treatment Market: Restraints

Precision in majority of affordable and conventional methods to diagnose hemoglobinopathy including electrophoresis and RBC count depends highly on skills and experience of technician carrying out the test. Absence of high specificity and sensitivity regarding major common diagnostic tests may lead to misinterpretation of the results due to human errors, which can to certain extent hamper the global hemoglobinopathy treatment market growth.

Key Takeaways:

Regular Red Blood Cell (RBC) count segment in the global hemoglobinopathy treatment market accounted for US$ 161.4 million in 2019 and is expected to reach US$ 277.9 million by 2027 at a CAGR of 7.4% during the forecast period. Regular RBC count is a regular test performed for diagnosis of prognosis of many diseases including hemoglobinopathies and infections. These factors are expected to aid this segment’s growth over the forecast period.

Request Here For PDF Brochure@ https://www.coherentmarketinsights.com/insight/request-pdf/2801

The segment of Sickle Cell Disease availed a dominant share in the global hemoglobinopathy treatment market in 2019, valuing 52.3% share, followed by β-thalassemia and α-thalassemia, respectively. As per the Center for Disease Control and Prevention, in 2016, nearly 100,000 population of the U.S. suffer from SCDs or sickle cell disorders. Sickle cell disorders are a lot more frequent among African Americans. Growing pervasiveness of the disorder will lead to rising demand for prevention and cure of sickle cell disease, thereby enhancing this segment’s growth over the forecast period.

The segment of diagnostic laboratories, in 2018, held a dominant spot in the global hemoglobinopathy treatment market, valuing it at 49.6%, succeeded by hospitals and clinics respectively. Initial testing is being performed for various diseases along with hemoglobinopathies by diagnostic laboratories. This aspect is expected to aid this segment’s growth over the forecast period.

Market Trends

Prenatal and premarital genetic testing to identify traits of sickle cell is rapidly getting popular in developed and developing nations. Screening for varied hemoglobinopathy disorders in new-borns is mandatory in the U.S.

There’s a global manifestation of sickle cell hemoglobinopathy, however its saturation is more in specific regions and ethnicities. It is believed to have emerged as a trait of resistance for malaria endemic at regions including Africa and some Asian countries such as India. A number of researches are being carried out to learn the correlation between hemoglobinopathy and malaria for developing better measures to diagnose and treat patients.

Global Hemoglobinopathy Treatment Market: Competitive Landscape

Key players functioning in the global hemoglobinopathy treatment market consists, Abbott Diagnostics, Bio-Rad Laboratories, AstraZeneca, Inc., Danaher Corp., Mindray Medical International Ltd., ReachBio Research Labs, Nexcelom Bioscience LLC, PerkinElmer Inc., Nihon Kohden Europe Ltd., Siemens Healthineers, Sysmex Europe GmbH, Bluebird Bio Inc., Acceleron Pharma Inc., and Celgene Corporation.

Buy This Premium Report@ https://www.coherentmarketinsights.com/insight/buy-now/2801

Global Hemoglobinopathy Treatment Market: Key Developments

June 2019: the European Medicines Agency (EMA) approved Bluebird Bio Inc. for Zynteglo, a gene therapy product consisting of autologous CD34+ cells encoding βA-T87Q-globin gene, to treat transfusion-dependent β-thalassemia without β0/β0 genotype

January 2019: Acceleron Pharma Inc. and Celgene Corporation began the clinical trial of a drug to treat adult patients suffering from beta-thalassemia- luspatercept

Segmentation

• By Test Type –
  • Routine Red Blood Cell (RBC) count
  • Hemoglobin solubility test
  • Hemoglobin electrophoresis (Hb ELP)
  • Hemoglobin isoelectric focusing ( Hb IEF)
  • Hemoglobin by high performance liquid chromatography
  • Genetic Testing
• By Indication –
  • Alpha Thalassemia
  • Beta Thalassemia
  • Sickle Cell Disease
• By End User –
  • Diagnostic Laboratories
  • Clinics
  • Hospitals
• By Region –
  • North America
  • Europe
  • Latin America
  • Asia Pacific
  • Africa
  • Middle East

Table of Contents

1. Research Objective and Assumption
   • Research Objectives
   • Assumptions
   • Abbreviations
2. Market Purview
   • Report Description
     • Market Definition and Scope
   • Executive Summary
     • Market Snippet, By Test Type
     • Market Snippet, By Indication
     • Market Snippet, By End User
   • Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
   • Market Dynamics
     • Drivers
     • Restraints
     • Market Opportunities
   • Impact Analysis
   • Key Developments
   • Regulatory Scenario
   • PEST Analysis
4. Global Hemoglobinopathy Market, By Test Type, 2019 – 2027 (US$ Mn)
   • Introduction
     • Market Share Analysis, 2019 and 2027 (%)
     • Y-o-Y Growth Analysis, 2017–2027
     • Segment Trends
   • Routine Red Blood Cell (RBC) count
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
     • Segment Trends
   • Genet~ic Testing
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
     • Segment Trends
   • Hemoglobin by high performance liquid chromatography
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
     • Segment Trends
   • Hemoglobin isoelectric focusing ( Hb IEF)
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
     • Segment Trends
   • Hemoglobin electrophoresis (Hb ELP)
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
     • Segment Trends
   • Hemoglobin solubility test
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
     • Segment Trends
5. Global Hemoglobinopathy Market, By Indications, 2019 – 2027 (US$ Mn)
   • Introduction
     • Market Share Analysis, 2019 and 2027 (%)
     • Y-o-Y Growth Analysis, 2017–2027
     • Segment Trends
   • Sickle Cell Disease
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
   • Beta Thalassemia
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
   • Alpha Thalassemia
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
6. Global Hemoglobinopathy Market, By End User, 2019 – 2027 (US$ Mn)
   • Introduction
     • Market Share Analysis, 2019 and 2027 (%)
     • Y-o-Y Growth Analysis, 2017–2027
     • Segment Trends
   • Hospitals
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
   • Diagnostic Laboratories
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
   • Clinics
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
7. Global Hemoglobinopathy Market, By Regions, 2019 – 2027 (US$ Mn)
   • Introduction
     • Market Share Analysis, 2019 and 2027 (%)
     • Y-o-Y Growth Analysis, 2017–2027
     • Segment Trends
   • North America
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
       • U.S.
       • Canada
   • Europe
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
       • U.K.
       • Germany
       • Italy
       • France
       • Spain
       • Russia
       • Rest of Europe
   • Asia Pacific
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
       • China
       • India
       • Japan
       • ASEAN
       • Australia
       • South Korea
       • Rest of Asia Pacific
   • Latin America
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
       • Brazil
       • Mexico
       • Argentina
       • Rest of Latin America
   • Middle East
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
       • GCC
       • Israel
       • Rest of Middle East
   • Africa
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
       • North Africa
       • Central Africa
       • South Africa

View Press Release: https://www.coherentmarketinsights.com/press-release/hemoglobinopathy-market-2939